Addus HomeCare Corporation

Fundamentals7.0
Price Action6.0
News Sentiment7.0
AI Rating
6.0

Key Drivers

  • High ROIC
  • Modest net margin
  • Large intangibles

AI
AI Summary

6.0

Addus now reads as a cash‑generative, capital‑efficient consolidator—organic same‑store personal‑care growth plus disciplined bolt‑ons are driving scalable margin improvement—but the investment thesis is contingent on CMS/home‑health reimbursement clarity and state rate approvals, with high intangible balances creating asymmetric downside if growth or M&A synergies falter. Actionable triggers to watch: CMS rule outcomes, key state Medicaid uplifts, and management keeping net leverage below ~1x while sustaining same‑store personal‑care growth (~5–7%+).

CashGenerative
RegulatoryRisk
MetricsToWatch‍

Price Chart

Loading chart...

Financial Metrics

-
Revenue (TTM)
-
Net Income (TTM)
-
EPS (Q)
-
MCAP

Deep Analysis

Research tool. Not personalized advice.

Fundamental Analysis

7.0

Key Financial Insights:

  • High ROIC
  • Modest net margin
  • Large intangibles

ADUS delivers strong cash conversion and very high ROIC with modest net margins and conservative leverage, but heavy intangibles and elevated SG&A constrain margin resilience.

efficient
intangible

Price Behavior

6.0
Research tool. Not personalized advice. Technical analysis is for informational purposes only.

Key Price Behavior Insights:

  • Moving-average resistance
  • Support at $99–$100
  • Volatile February spike

ADUS is in a short-term downtrend with the last-month moving average (~$104) above the $99.28 close, showing distribution and momentum exhaustion, but with near-term support around $99–$100 that could cap immediate losses while a reclaim above ~$104 would shift the bias back to buyers.

bearish
watchlist
Support Level: $99–$100
Resistance Level: $104 (last month MA) and $117.63 (February high)

Sharp spike to $117.63 on 2026-02-23 followed by steady retracement indicating profit-taking and elevated tail risk

Sentiment & News

7.0

Key News Insights:

  • Revenue beat
  • EPS growth
  • Rising short interest

Addus HomeCare beat Q4 and FY25 expectations with strong revenue and adjusted EPS growth, rising adjusted EBITDA, active investor engagement, but also a notable increase in short interest.

Outperformance
Healthcare

Positive operational momentum and investor attention should support the stock near term, though elevated short interest adds downside risk to sentiment